---
title: "Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Product information and disease description"
description: "Formulary evidence on Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Product information and disease description. Covers Product description and Place of product in therapy. 132 evidence topics quoted from 38 sources."
canonical: "https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/product-information-and-disease-description"
published: "2026-09-28T12:24:10-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Approved; BLA resubmitted May 2026 and approved July 2026

> “ISELIN, N.J., July 24, 2026”
> “today announced that the U.S. Food and Drug Administration (FDA) has approved LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (nAMD)”

Source: [Outlook Therapeutics FDA approval announcement (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/tm2621316d1_ex99-1.htm)

> “Please refer to your biologics license application (BLA) dated and received August 29, 2022, and your amendments, submitted under section 351(a) of the Public Health Service Act for Lytenava (bevacizumab-vikg) injection. We acknowledge receipt of your resubmission dated May 29, 2026, which constituted a complete response to our December 30, 2025, action letter.”
> “We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.”

Source: [FDA (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761320Orig1s000ltr.pdf)

> “Initial U.S. Approval: 2026”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.1-2"></a>

##### Launch: Anticipated before the end of 2026

> “Outlook Therapeutics expects to make LYTENAVA™ available to eligible patients in the United States before year-end.”

Source: [Outlook Therapeutics FDA approval announcement (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/tm2621316d1_ex99-1.htm)

> “The Company continues to advance preparations for the U.S. commercial launch of LYTENAVA, the only FDA-approved ophthalmic bevacizumab for the treatment of wet age-related macular degeneration (wet AMD).”
> “Outlook Therapeutics is advancing preparations for the U.S. commercial launch of LYTENAVA, planned before the end of calendar 2026.”

Source: [Outlook Therapeutics third quarter fiscal year 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/tm2622399d3_ex99-1.htm)

<a id="topic-2.1.1-3"></a>

##### Regulatory history: first Complete Response Letter

> “the U.S. Food and Drug Administration (FDA) has issued a CRL to the Company's BLA for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD. While the FDA acknowledged the NORSE TWO pivotal trial met its safety and efficacy endpoints, the Agency concluded it could not approve the BLA during this review cycle due to several CMC issues, open observations from pre-approval manufacturing inspections, and a lack of substantial evidence.”
> “The FDA accepted Outlook Therapeutics' BLA submission for ONS-5010 to treat wet AMD with an initial PDUFA goal date of August 29, 2023; FDA did not approve the BLA during this review cycle and the Company is working with the FDA to address the issues that have been raised so that the BLA may be re-submitted.”

Source: [Outlook Therapeutics regulatory update (2023)](https://www.sec.gov/Archives/edgar/data/1649989/000110465923096669/tm2325118d1_ex99-1.htm)

<a id="topic-2.1.1-4"></a>

##### Regulatory history: NORSE EIGHT trial, second and third Complete Response Letters

> “In the fourth quarter of calendar 2023, the Company agreed to conduct an additional adequate and well-controlled clinical trial to support its Biologics License Application (“BLA”) for LYTENAVA. The Company submitted a Special Protocol Assessment (“SPA”) for the NORSE EIGHT study in December 2023, and in January 2024 the U.S. Food and Drug Administration (the “FDA”) agreed that the protocol, if successful, would satisfy the requirement for a second adequate and well-controlled trial. The Company also identified approaches to address the Chemistry, Manufacturing, and Controls (“CMC”) comments in the Complete Response Letter (“CRL”). In November 2024, the Company announced that NORSE EIGHT did not meet the pre-specified non-inferiority endpoint; however, results demonstrated improvements in vision, evidence of biologic activity, and a favorable safety profile, which were further supported by the full week 12 data set. The Company resubmitted the BLA in February 2025. On August 27, 2025, the FDA issued a second CRL citing a single deficiency related to substantial evidence of effectiveness and recommended submission of confirmatory efficacy data, while reaffirming that the NORSE TWO trial met its primary endpoint. Following a Type A meeting in September 2025, the Company resubmitted the BLA on November 3, 2025, and received a third CRL on December 31, 2025.”
> “Following receipt of the CRL in December 2025, the Company engaged with the FDA on multiple occasions, including a formal Type A meeting held on March 2, 2026, which led to the submission of a formal dispute resolution meeting request. In April 2026, the meeting with the deciding official was conducted as part of the Company's ongoing efforts to align with the FDA regarding the regulatory pathway for LYTENAVA™ (bevacizumab-vikg).”

Source: [Outlook Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926098415/otlk-20260630x10q.htm)

<a id="topic-2.1.1-5"></a>

##### Regulatory history: resubmission acceptance and final approval

> “the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the resubmission of the Biologics License Application (BLA) for ONS-5010/LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD), or wet AMD. The Company has been informed that the resubmission is a Class 1 review, with a PDUFA target action date of July 29, 2026.”
> “Outlook Therapeutics has initiated pre-launch activities in anticipation of the pending BLA approval.”

Source: [Outlook Therapeutics FDA acceptance announcement (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926074346/tm2618010d1_ex99-1.htm)

> “today announced that the U.S. Food and Drug Administration (FDA) has approved LYTENAVA™ (bevacizumab-vikg) for the treatment of neovascular age-related macular degeneration (nAMD), commonly known as wet AMD.”
> “The approval establishes LYTENAVA™ as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the United States.”
> “the Company anticipates that the approval will provide LYTENAVA with 12 years of Reference Product Exclusivity under the BPCIA.”

Source: [Outlook Therapeutics FDA approval announcement (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/tm2621316d1_ex99-1.htm)

<a id="topic-2.1.1-6"></a>

##### Regulatory history: European Union and United Kingdom approval and launch

> “In May 2024 the Company received Marketing Authorization from the European Commission for LYTENAVA (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (“AMD”) in the European Union (“EU”). Additionally, in July 2024 the Company also received marketing authorization for LYTENAVA (bevacizumab gamma) in the United Kingdom (“UK”) from the UK Medicines and Healthcare products Regulatory Agency (“MHRA”). LYTENAVA (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU and UK. In June 2025, the Company launched LYTENAVA commercially in both Germany and the UK, and commenced commercial sales in those countries.”

Source: [Outlook Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926098415/otlk-20260630x10q.htm)

> “In Europe, Outlook Therapeutics continues to expand the commercialization of LYTENAVA in Germany, Austria and the United Kingdom. The Company is also preparing for a planned launch in the Netherlands later in 2026 following its Netherlands submission. In Switzerland, the Company's partner, Mediconsult, is leading regulatory and commercial activities in support of an anticipated launch in 2027.”

Source: [Outlook Therapeutics third quarter fiscal year 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/tm2622399d3_ex99-1.htm)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Outlook Therapeutics

> “LYTENAVA™ (bevacizumab-vikg) Manufactured by: LYTENAVA is a trademark of Outlook Therapeutics, Inc. Outlook Therapeutics, Inc. ©2026 Outlook Therapeutics Inc. 111 S. Wood Ave, Unit #100 Iselin, NJ 08830 U.S. U.S. License No.: 2292”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.1-2"></a>

###### Generic and brand names, therapeutic class

> “LYTENAVA™ (bevacizumab-vikg) injection, for intravitreal use”
> “LYTENAVA is a vascular endothelial growth factor (VEGF) inhibitor”
> “LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.1-3"></a>

###### Development code name and prior identity

> “ONS-5010 is an investigational ophthalmic formulation of bevacizumab under development as an intravitreal injection for the treatment of wet AMD and other retinal diseases.”

Source: [Outlook Therapeutics regulatory update (2023)](https://www.sec.gov/Archives/edgar/data/1649989/000110465923096669/tm2325118d1_ex99-1.htm)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Dosage form and strength

> “Injection: 1.25 mg (0.05 mL of 25 mg/mL) colorless to light brown, opalescent solution for intravitreal injection in a single-dose vial.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.2-2"></a>

###### How supplied

> “LYTENAVA (bevacizumab-vikg) injection is a colorless to light brown, opalescent solution. Each carton (NDC 82491-025-10) contains LYTENAVA 1.25 mg (0.05 mL of 25 mg/mL bevacizumab-vikg solution) in a single-dose glass vial with a BLUE CAP.”
> “EACH CARTON IS FOR SINGLE-EYE USE ONLY.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.2-3"></a>

###### Storage and handling

> “Store LYTENAVA refrigerated at 2oC to 8oC (36oF to 46oF) in the original carton until use to protect from light. DO NOT FREEZE.”
> “Prior to use, the unopened glass vial of LYTENAVA may be kept at room temperature, 20oC to 25oC (68oF to 77oF), for up to 12 hours. Ensure the injection is given immediately after preparation of the dose.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.2-4"></a>

###### Composition

> “LYTENAVA is supplied in a single-dose vial designed to deliver 0.05 mL of 25 mg/mL (1.25 mg) aqueous solution that also contains dibasic sodium phosphate (0.06 mg), monobasic sodium phosphate (0.29 mg), polysorbate 20 (0.02 mg), trehalose (2.71 mg), and Water for Injection. The pH is 6.”
> “LYTENAVA (bevacizumab-vikg) injection is a sterile, colorless to light brown, opalescent solution for intravitreal use. LYTENAVA does not contain an anti-microbial preservative.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

<a id="topic-2.1.2.3-1"></a>

###### Summary: estimated monthly and annual cost

- Price basis: U.S. wholesale acquisition cost of $485 per vial, established by Outlook Therapeutics on September 16, 2026; each carton holds one 1.25 mg single-dose vial. No average sales price or product-specific HCPCS payment limit had been published as of November 17, 2026.
- Dosing basis: 1.25 mg (one vial) per treated eye by intravitreal injection once monthly (approximately 28 days), the only dosing interval the prescribing information states; each vial treats a single eye, and a second eye requires a separate vial.
- Base case: one eye treated monthly, $485 per vial × 12 injections per year = $5,820 per year; ÷ 12 = $485 per month.
- Range: $5,820 to $12,610 per year ($485 to $1,051 per month). The upper bound is both eyes treated every 28 days: 2 vials × $485 × 13 injections per year = $12,610 per year; ÷ 12 = $1,051 per month. Intermediate values are one eye every 28 days ($485 × 13 = $6,305 per year; $525 per month) and both eyes monthly (2 × $485 × 12 = $11,640 per year; $970 per month).
- Rationale for the range: the label defines monthly as approximately 28 days, which yields 12 to 13 injections per year; bilateral disease doubles the number of vials because the label restricts each vial to one eye; the label states no loading phase, extended interval, or dose reduction, so less frequent dosing falls outside the labeled regimen and is not included.
- Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.

Source: [Outlook Therapeutics Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926108952/tm2625694d1_8k.htm); [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.3-2"></a>

###### Wholesale acquisition cost

> “On September 16, 2026, Outlook Therapeutics, Inc. established the wholesale acquisition cost for LYTENAVA™ in the United States of $485 per vial.”

Source: [Outlook Therapeutics Form 8-K (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926108952/tm2625694d1_8k.htm)

<a id="topic-2.1.2.3-3"></a>

###### Average sales price

No evidence found.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

No evidence found.

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Indication

> “LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Mechanism of action

> “Bevacizumab is a human vascular endothelial growth factor (VEGF) inhibitor. Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells.”
> “LYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses endothelial cell proliferation, neovascularization, and vascular permeability. Inhibition of such activity targets a pathophysiologic process that contributes to vision loss.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Central foveal thickness as a pharmacodynamic marker

> “Increased retinal thickness (e.g., central foveal thickness (CFT)) and leakage of blood and fluid from choroidal neovascularization is associated with nAMD. CFT is known to be a reproducible, early indication of pharmacodynamic response to anti-VEGF treatments.”
> “Changes in CFT were assessed using optical coherence tomography in NORSE TWO and NORSE EIGHT [see Clinical Studies (14)]. Increasingly greater reductions in CFT were observed at Weeks 4, 8, and 12 across both treatment arms.”
> “Anatomic data were not used to influence LYTENAVA treatment decisions.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Systemic pharmacokinetics after intravitreal injection

> “Following intravitreal administration of LYTENAVA, the systemic exposure to bevacizumab-vikg is minimal.”
> “In 14 subjects who received a single 1.25 mg dose of LYTENAVA, the serum bevacizumab-vikg concentration was assessed up to Day 4. The serum bevacizumab-vikg concentrations gradually increased over time, so the highest concentrations observed were approximately at Day 4 (the last collection time) ranging from 33 to 270 ng/mL, which was <1% of the Cmax after intravenous infusion of 2 mg/kg bevacizumab-vikg. However, due to the limited sample collection, Cmax or AUC could not be adequately characterized.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.6.3-2"></a>

###### Immunogenicity

> “The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies, including those of LYTENAVA or of other bevacizumab products.”
> “In a 52-week study, a total of 14 subjects who received LYTENAVA and were subsequently evaluated for immunogenicity did not show detectable ADA at any timepoint but the ADA assay sensitivity data in the presence of free drug was insufficient. However, due to the minimal systemic exposure to LYTENAVA following intravitreal injection, the risk of immunogenicity is not expected to be clinically significant.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### Contraindications

> “LYTENAVA is contraindicated in patients with ocular or periocular infections.”
> “LYTENAVA is contraindicated in patients with active intraocular inflammation.”
> “LYTENAVA is contraindicated in patients with known hypersensitivity to bevacizumab products or any of the ingredients in LYTENAVA. Hypersensitivity reactions may manifest as severe intraocular inflammation.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.7.1-2"></a>

###### Warning: endophthalmitis and retinal detachments

> “Intravitreal injections have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique should always be used when administering LYTENAVA. In addition, patients should be monitored following the injection to permit early treatment should an infection occur [see Dosage and Administration (2.3) and Patient Counseling Information (17)].”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.7.1-3"></a>

###### Warning: increases in intraocular pressure

> “Increases in intraocular pressure have been noted post-injection (up to 60 minutes) while being treated with LYTENAVA. Monitor intraocular pressure prior to and following intravitreal injection with LYTENAVA and manage appropriately [see Dosage and Administration (2.4)].”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.7.1-4"></a>

###### Warning: thromboembolic events

> “Although there was a low rate of arterial thromboembolic events (ATEs) observed in the LYTENAVA clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.7.1-5"></a>

###### Adverse reactions: clinical trial exposure and most common reaction

> “The data described below reflect exposure to LYTENAVA in 601 patients, in five clinical trials [see Clinical Studies (14)].”
> “Most common adverse reaction (≥ 4%) reported in patients receiving LYTENAVA was conjunctival hemorrhage (4%) (6.1).”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.7.1-6"></a>

###### Adverse reactions: common ocular events versus ranibizumab

| Adverse Reactions | LYTENAVA 1.25 mg (N = 601) | Ranibizumab 0.5 mg (N = 345) |
| --- | --- | --- |
| Conjunctival hemorrhage | “4%” | “3%” |
| Eye pain | “2%” | “1%” |
| Vitreous floaters | “2%” | “1%” |

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.7.1-7"></a>

###### Adverse reactions: less common ocular events

> “Less common ocular adverse reactions reported in the study eye in <1% of patients treated with LYTENAVA were corneal abrasion, dry eye, eye irritation, and intraocular pressure increased.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Pregnancy

> “Based on the anti-VEGF mechanism of action for bevacizumab products [see Clinical Pharmacology (12.1)], treatment with LYTENAVA may pose a risk to human embryofetal development.”
> “There are no adequate and well-controlled studies of LYTENAVA administration in pregnant women or pregnant animals. It is not known whether bevacizumab-vikg can cause fetal harm when administered to a pregnant woman. LYTENAVA should be given to a pregnant woman only if clearly needed.”
> “All pregnancies have a background risk of birth defect, loss, and other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.8-2"></a>

###### Lactation

> “There are no data available on the presence of bevacizumab-vikg in human milk, the effects of bevacizumab-vikg on the breastfed infant or the effects of bevacizumab-vikg on milk production/excretion.”
> “Because many drugs are excreted in human milk, and because the potential for absorption and harm to infant growth and development exists, caution should be exercised when LYTENAVA is administered to a nursing woman.”
> “The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for LYTENAVA and any potential adverse effects on the breastfed child from bevacizumab-vikg.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.8-3"></a>

###### Females and males of reproductive potential

> “Females of reproductive potential should use effective contraception during treatment with LYTENAVA and for at least 3 months after the last dose when stopping treatment with LYTENAVA.”
> “There are no data regarding the effects of LYTENAVA on human fertility. Based on the anti-VEGF mechanism of action LYTENAVA may pose a risk to reproductive capacity [see Clinical Pharmacology (12.1)].”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.8-4"></a>

###### Pediatric use

> “The safety and effectiveness of LYTENAVA in pediatric patients have not been established.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.8-5"></a>

###### Geriatric use

> “In the three completed Phase 3 clinical studies, approximately 70% (238/341) of patients treated with LYTENAVA were ≥ 65 years of age and approximately 47 % (160/341) were ≥ 75 years of age. No overall differences in efficacy or safety were seen with increasing age in these studies [see Clinical Studies (14)].”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Bevacizumab-vikg

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Bevacizumab-vikg on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Recommended dose and dosing interval

> “FOR OPHTHALMIC INTRAVITREAL INJECTION. LYTENAVA must only be administered by a qualified physician.”
> “The recommended dose for LYTENAVA is 1.25 mg (0.05 mL of 25 mg/mL) administered by intravitreal injection once monthly (approximately 28 days).”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Required devices and preparation

> “A 5-micron sterile filter needle (18-gauge x 1½-inch), a 1-mL syringe (with marking to measure 0.05 mL), and a 30-gauge x ½-inch sterile injection needle are needed.”
> “The glass vial is for one-time use in one eye only.”
> “Using aseptic technique, the total vial volume of a LYTENAVA vial should be withdrawn through a 5-micron (18-gauge x 1½-inch) sterile filter needle attached to a 1 mL syringe. The filter needle should be discarded after withdrawal of the vial contents and should not be used for the intravitreal injection. The filter needle should be replaced with a sterile 30-gauge x ½-inch needle for the intravitreal injection. The contents should be expelled until the plunger tip is aligned with the line that marks 0.05 mL on the syringe.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.10.2-2"></a>

###### Injection procedure and post-injection monitoring

> “The intravitreal injection procedure should be carried out under controlled aseptic conditions, which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide should be given prior to injection.”
> “Prior to and 30 minutes following the intravitreal injection, patients should be monitored for elevation in intraocular pressure using tonometry. Monitoring may also consist of a check for perfusion of the optic nerve head immediately after the injection [see Warnings and Precautions (5.2)]. Patients should also be monitored for and instructed to report any symptoms suggestive of endophthalmitis without delay following the injection [see Warnings and Precautions (5.1)].”
> “Each single-dose vial should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new vial should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter needle, and injection needles should be changed before LYTENAVA is administered to the other eye.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Pre-launch preparation and planned launch timing

> “Outlook Therapeutics has initiated pre-launch activities in anticipation of the pending BLA approval.”

Source: [Outlook Therapeutics FDA acceptance announcement (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926074346/tm2618010d1_ex99-1.htm)

> “Outlook Therapeutics expects to make LYTENAVA™ available to eligible patients in the United States before year-end. The Company is committed to providing broad patient access support services through comprehensive reimbursement and patient assistance programs designed to help physicians integrate LYTENAVA™ into routine clinical practice for wet AMD.”

Source: [Outlook Therapeutics FDA approval announcement (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/tm2621316d1_ex99-1.htm)

<a id="topic-2.1.2.11-2"></a>

###### Distribution and logistics partner

> “As part of the Company's multi-year commercial planning process, Outlook Therapeutics and AmerisourceBergen entered into a strategic commercialization agreement to expand the Company's reach for connecting to retina specialists and their patients. AmerisourceBergen will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services and other services in the United States.”

Source: [Outlook Therapeutics regulatory update (2023)](https://www.sec.gov/Archives/edgar/data/1649989/000110465923096669/tm2325118d1_ex99-1.htm)

<a id="topic-2.1.2.11-3"></a>

###### Reimbursement coding and payer access strategy

> “Advancing the U.S. launch strategy for LYTENAVA, including broad market access, reimbursement, pricing, medical affairs, and supply capabilities”
> “As part of these efforts, the Company plans to submit an application for a permanent Healthcare Common Procedure Coding System or HCPCS code by October 1, 2026, to support reimbursement following launch.”
> “The Company's launch and go-to-market strategy is designed to reflect the evolving biosimilar landscape, affordability considerations, and the potential for additional market entrants, while supporting broad patient access and reimbursement.”
> “Our launch strategy reflects a deep understanding of the retina market and the needs of patients, physicians, practices, and payers”
> “We are taking a targeted approach to customer engagement, pricing, and reimbursement, while building the commercial and supply capabilities needed to support the introduction of LYTENAVA in the United States.”

Source: [Outlook Therapeutics third quarter fiscal year 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/tm2622399d3_ex99-1.htm)

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

No evidence found.

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Bevacizumab-vikg on Quality Measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### NORSE TWO: LYTENAVA versus ranibizumab, dosing regimens and primary endpoint at Month 11

> “In NORSE TWO, adult patients with nAMD were randomized to LYTENAVA 1.25 mg (N=113) administered once monthly for 1 year or ranibizumab 0.5 mg (N=115) administered once monthly for 3 months (Days 0, 30, and 60) followed by once every 3 months for 1 year (Days 150 and 240). Patient ages ranged from 54 to 98 years, with a median age of 79 years.”
> “The primary efficacy endpoint was the proportion of patients who gained ≥ 15 Best Corrected Visual Acuity (BCVA) letters from baseline to Month 11 as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score. The difference observed between the study drug groups was significant, in favor of LYTENAVA (see Table 2).”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.14-2"></a>

###### NORSE TWO: patients gaining 15 or more ETDRS letters at 11 months

| Field | LYTENAVA 1.25 mg once monthly (N = 113) | Ranibizumab 0.5 mg once monthly x 3 months then every 3 months (N = 115) |
| --- | --- | --- |
| Number of subjects, n/N (%) | “45/108 (41.7)” | “24/104 (23.1)” |

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.14-3"></a>

###### NORSE TWO: risk difference between LYTENAVA and ranibizumab

> “Risk difference 0.1859 95% CI 0.0442, 0.3086”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

###### NORSE EIGHT: LYTENAVA versus ranibizumab, non-inferiority at Week 8

> “In a multicenter, randomized, masked, controlled study (NORSE EIGHT – NCT06190093), 400 adult patients with nAMD were randomized (1:1) to LYTENAVA 1.25 mg or ranibizumab 0.5 mg, administered every 4 weeks for 3 total doses (Day 0, Week 4, and Week 8). The primary efficacy endpoint was the mean change in baseline BCVA as measured by ETDRS score at Week 8 using a non-inferiority (NI) margin of -3.5 letters.”
> “NORSE EIGHT did not meet its pre-specified NI margin of -3.5 letters in mean change from baseline BCVA at Week 8 compared to ranibizumab.”
> “At Week 8, the LYTENAVA group had a mean increase in BCVA of 3.3 compared to a mean increase of 4.5 in the ranibizumab group. The LS mean difference and 95% CI was -2.3 (-4.0, -0.5).”
> “LYTENAVA showed an increase from baseline in BCVA at Week 12 consistent with NORSE TWO.”

Source: [Outlook Therapeutics, Inc. (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761320s000lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Comparison with unapproved compounded bevacizumab

> “Because no FDA-approved ophthalmic formulations of bevacizumab are available currently, clinicians wishing to treat retinal patients with bevacizumab have had to use unapproved repackaged IV bevacizumab provided by compounding pharmacies—products that have known risks of contamination and inconsistent potency and availability. If approved, ONS-5010 would provide an FDA-approved option for physicians that currently have no choice but to prescribe unapproved repackaged oncologic IV bevacizumab from compounding pharmacies for the treatment of wet AMD.”

Source: [Outlook Therapeutics regulatory update (2023)](https://www.sec.gov/Archives/edgar/data/1649989/000110465923096669/tm2325118d1_ex99-1.htm)

> “Rather than relying on repackaged formulations originally intended for intravenous use, physicians now have access to a purpose-built ophthalmic formulation of bevacizumab designed specifically for intravitreal administration that delivers the manufacturing consistency, product quality, and regulatory oversight patients deserve.”
> “Bevacizumab already accounts for the majority of first-line anti-VEGF treatment in wet AMD, underscoring its important role in retina care.”

Source: [Outlook Therapeutics FDA approval announcement (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/tm2621316d1_ex99-1.htm)

<a id="topic-2.1.2.14-6"></a>

###### Market size and competitive landscape

> “The U.S. anti-VEGF retina market is estimated at approximately $8.5 billion annually, with millions of intravitreal injections administered every year.”

Source: [Outlook Therapeutics FDA approval announcement (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926086685/tm2621316d1_ex99-1.htm)

> “The Company's launch and go-to-market strategy is designed to reflect the evolving biosimilar landscape, affordability considerations, and the potential for additional market entrants, while supporting broad patient access and reimbursement.”

Source: [Outlook Therapeutics third quarter fiscal year 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/tm2622399d3_ex99-1.htm)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Definition of age-related macular degeneration

> “Age-related macular degeneration (AMD) is an eye disease that can blur your central vision.”

Source: [National Eye Institute age-related macular degeneration page](https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration)

<a id="topic-2.2.1.1-2"></a>

###### Dry and wet forms of AMD

> “Most people with AMD have dry AMD (also called atrophic AMD). This is when the macula gets thinner with age.”
> “Wet AMD (also called advanced neovascular AMD), is a less common type of late AMD that usually causes faster vision loss.”
> “It happens when abnormal blood vessels grow in the back of the eye and damage the macula.”

Source: [National Eye Institute age-related macular degeneration page](https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration)

<a id="topic-2.2.1.1-3"></a>

###### Neovascular AMD as a distinct clinical entity

> “Neovascular age-related macular degeneration (exudative or wet AMD) is a prevalent, progressive retinal degenerative macular disease that is characterized by neovascularization of the choroid”

Source: [Pugazhendhi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7866170/)

<a id="topic-2.2.1.1-4"></a>

###### Etiology: age as the leading risk factor

> “Your risk for AMD increases as you get older. People age 55 and older are more likely to have AMD.”

Source: [National Eye Institute age-related macular degeneration page](https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration)

> “Increasing age is the strongest demographic and leading risk factor associated with AMD”

Source: [Pugazhendhi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7866170/)

<a id="topic-2.2.1.1-5"></a>

###### Etiology: family history, race, and smoking

> “The risk for AMD is also higher for people who: Have a family history of AMD Are Caucasian Smoke”

Source: [National Eye Institute age-related macular degeneration page](https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration)

> “Pooled data from the Rotterdam, Beaver Dam Eye, and Blue Mountains studies report a positive correlation with a 2–4-fold likelihood of developing any type of AMD in smokers when compared to non-smokers”

Source: [Pugazhendhi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7866170/)

> “Numerous studies have reported that Caucasians are more likely to develop AMD than blacks, including the Baltimore Eye Study, which reported a four-fold higher risk in whites than in blacks”

Source: [Pugazhendhi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7866170/)

<a id="topic-2.2.1.1-6"></a>

###### Anatomic basis: the retinal pigment epithelium, Bruch's membrane, and drusen

> “Damage to the retinal pigment epithelium (RPE) is considered to be a hallmark of AMD.”
> “Age‐related structural abnormalities within Bruch's membrane have also been associated with AMD.”
> “The AMD spectrum spans early‐stage AMD, during which drusen, pigment epithelial detachment (PED) and vitelliform lesions are observed, to late stage AMD, with choroidal neovascularization (CNV, neovascular AMD) or geographic atrophy (GA).”

Source: [Somasundaran et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7754492/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Neovascular age-related macular degeneration

<a id="topic-2.2.1.2.1-1"></a>

###### Global incidence trend, 2006 to 2020

> “The incidence of nAMD was 71 (95% CI 55–90) and 102 (95% CI 88–118) per 100,000 person years in 2006 and 2020, respectively.”

Source: [Korva-Gurung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10262804/)

<a id="topic-2.2.1.2.1-2"></a>

###### Incidence by age group

> “In the age group of 75–84 years, the incidence increased 1.2-fold from 300 in 2006 to 366 in 2020.”
> “The increase in the age group of 85–96 years was 2.4-fold from 200 in 2006 to 471 in 2020.”

Source: [Korva-Gurung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10262804/)

<a id="topic-2.2.1.2.1-3"></a>

###### Incidence by sex

> “The incidence of nAMD in women was almost two-fold greater compared to males at the same age.”

Source: [Korva-Gurung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10262804/)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Neovascular age-related macular degeneration

<a id="topic-2.2.1.2.2-1"></a>

###### Global prevalence and projected growth

> “the number of people suffering from AMD is expected to increase from 196 million in 2020 to 288 million in 2040”

Source: [Huang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11534605/)

<a id="topic-2.2.1.2.2-2"></a>

###### Prevalence in a population-based cohort

> “The prevalence of nAMD was 862 (/100,000 inhabitants) (95% CI 821–906) in adults aged 44–96 years in 2020.”
> “In the oldest 75–84 and 85–96 age categories the nAMD prevalence was 2865/100,000 (3%, 95% CI 2665–3079) and 2620/100,000 (3%, 95% CI 2323–2956), respectively.”

Source: [Korva-Gurung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10262804/)

<a id="topic-2.2.1.2.2-3"></a>

###### United States prevalence among Medicare beneficiaries

> “the prevalence of wet AMD remained relatively stable, fluctuating from 2.17% in 2014 to 2.14% in 2021.”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12705084/)

<a id="topic-2.2.1.2.2-4"></a>

###### Prevalence by race and ethnicity

> “the prevalence of wet AMD showed a progressive decrease across White, Native American, Asian, Hispanic, and Black populations”

Source: [Singh et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12705084/)

<a id="topic-2.2.1.2.2-5"></a>

###### United States burden estimates

> “Nearly 20 million U.S. adults are living with some form of age-related macular degeneration.”
> “Wet macular degeneration accounts for approximately 10% of all AMD cases but is responsible for 90% of legal blindness.”

Source: [BrightFocus Foundation](https://www.brightfocus.org/macular/facts-figures/)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Untreated disease course

> “Prior to the anti-VEGF era, the clinical manifestation of the natural history of nAMD was the formation of a disciform scar and blindness”
> “AMD leads to blindness when left untreated, due to the development of atrophy and/or disciform scar.”

Source: [Armendariz et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11584703/)

<a id="topic-2.2.1.3-2"></a>

###### Magnitude of untreated vision loss

> “ranibizumab not only prevented loss of vision in nAMD treatment-naïve patients (the natural history for these patients), but also, and for the first time ever in this disease, that their vision could recover, as shown by the 7.2 letters gained on average in the ranibizumab 0.5 mg dose group (the dose subsequently marketed) versus an average loss of 10.4 letters by the sham group.”

Source: [Armendariz et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11584703/)

<a id="topic-2.2.1.3-3"></a>

###### Scarring despite treatment

> “Scar tissue was detected in approximately half of the patients after two years of intensive treatment”

Source: [Armendariz et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11584703/)

<a id="topic-2.2.1.3-4"></a>

###### Contribution to overall disease burden

> “While less common than dry AMD, wet or nvAMD accounts for almost 90% of blindness associated with AMD.”

Source: [Pugazhendhi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7866170/)

<a id="topic-2.2.1.3-5"></a>

###### Mortality attributable to neovascular AMD

No evidence found.

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Choroidal neovascularization

> “Neovascular AMD, wherein abnormal vessels break through Bruch's membrane (Figure 2) is one of the leading causes of blindness in the West”

Source: [Pugazhendhi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7866170/)

<a id="topic-2.2.1.4-2"></a>

###### Role of vascular endothelial growth factor

> “VEGF-A strongly inducing vascular proliferation and migration of endothelial cells essential for both physiological and pathological angiogenesis”

Source: [Pugazhendhi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7866170/)

<a id="topic-2.2.1.4-3"></a>

###### Progression from early disease to neovascular disease

> “The AMD spectrum spans early‐stage AMD, during which drusen, pigment epithelial detachment (PED) and vitelliform lesions are observed, to late stage AMD, with choroidal neovascularization (CNV, neovascular AMD) or geographic atrophy (GA).”

Source: [Somasundaran et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7754492/)

<a id="topic-2.2.1.4-4"></a>

###### Fibrotic end stage

> “Disciform degeneration was defined as "fibrous tissue proliferation beneath the pigment epithelium or retina" by Green in 1977”

Source: [Armendariz et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11584703/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Amsler grid self-monitoring

> “The Amsler grid consists of horizontal and vertical lines intersecting at a central fixation point.”
> “the patient assesses whether the lines are parallel or show distortion (metamorphopsia).”

Source: [Estreicher et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12912174/)

<a id="topic-2.2.1.5-2"></a>

###### Optical coherence tomography

> “Your doctor may also recommend doing a test called optical coherence tomography (OCT).”

Source: [National Eye Institute age-related macular degeneration page](https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration)

<a id="topic-2.2.1.5-3"></a>

###### Optical coherence tomography angiography

> “Optical coherence tomography angiography (OCTA) is a non-invasive imaging technique that allows visualization of retinal and choroidal blood vessels by detecting motion contrast caused by blood flow.”
> “Unlike traditional dye-based angiographic methods, such as fluorescein angiography (FA) or indocyanine green angiography (ICGA), OCTA does not require intravenous contrast agents and can capture volumetric data within seconds.”

Source: [Lombardo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12532941/)

<a id="topic-2.2.1.5-4"></a>

###### Home optical coherence tomography as an adjunct to office-based diagnosis

> “Home-based optical coherence tomography (OCT) has emerged as a potential tool to bridge this surveillance gap by enabling frequent, patient-administered imaging between office visits”

Source: [Sambhara et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13413994/)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Visual symptoms: central vision blur and distortion

> “Age-related macular degeneration (AMD) is an eye disease that can blur your central vision.”

Source: [National Eye Institute age-related macular degeneration page](https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration)

> “waviness, blurring, or gaps, which may indicate macular pathology.”

Source: [Estreicher et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12912174/)

<a id="topic-2.2.1.6-2"></a>

###### Vascular signs: leaking, abnormal blood vessels

> “It happens when abnormal blood vessels grow in the back of the eye and damage the macula.”

Source: [National Eye Institute age-related macular degeneration page](https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration)

<a id="topic-2.2.1.6-3"></a>

###### Functional impact: activities requiring central vision

> “AMD doesn't cause complete blindness, but losing your central vision can make it harder to see faces, read, drive, or do close-up work like cooking or fixing things around the house.”

Source: [National Eye Institute age-related macular degeneration page](https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Falls and fall-related injury

> “They are twice as common among older people with AMD”

Source: [White et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8802008/)

> “35% of the participants reporting that they had incurred injuries during a fall”

Source: [White et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8802008/)

<a id="topic-2.2.1.7-2"></a>

###### Concern about falling

> “high CF (FES-I ≥ 23) was identified in just under half of the participants (48%) at baseline, and the proportion increased significantly to 65% at follow-up”

Source: [White et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8802008/)

<a id="topic-2.2.1.7-3"></a>

###### Anxiety and depression

> “Clinically significant severity of depression symptoms was found in 4.2% of patients, mild manifestations of depression were found in 8.3%”
> “79.2% demonstrated moderate reactive anxiety; 12.5% of the subjects had a low level of reactive anxiety. 81.7 % of the respondents were subject to moderate and high personal anxiety.”

Source: [Kuzmina and Yakovlev (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12437679/)

<a id="topic-2.2.1.7-4"></a>

###### Progressive fibrotic scarring

> “large disciform scars are rarely encountered in the clinic. However long-term studies show that smaller and less severe fibrotic scars are not uncommon and develop over time despite optimal treatment.”

Source: [Armendariz et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11584703/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Neovascular age-related macular degeneration

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Treatment-day time burden

> “The majority of patients reported to spend 1–3 hours (43.1%), followed by 4–6 hours (30.8%)”

Source: [Reitan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10226541/)

<a id="topic-2.2.1.8.1-2"></a>

###### Emotional burden of injection visits

> “Patients reported that they were nervous or struggled to sleep prior to treatment”
> “33.1% of patients reported to be stressed and 15.4% struggled to sleep”
> “The majority of patients reported the treatment as uncomfortable (54.6%) or as somewhat painful (26.2%)”

Source: [Reitan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10226541/)

<a id="topic-2.2.1.8.1-3"></a>

###### Caregiver involvement in treatment visits

> “Approximately half of the patients required caregiver support every visit (37.7%) or occasionally (14.6%)”

Source: [Reitan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10226541/)

<a id="topic-2.2.1.8.1-4"></a>

###### Falls-related concern and quality of life

> “Concern about falling is another common issue for older people, with far-reaching implications including activity restriction, reduced quality of life”

Source: [White et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8802008/)

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Annual per-patient cost

> “We estimated an annual all-cause cost for patients with nAMD of $24,520 per patient”
> “newly diagnosed patients incurred slightly lower costs ($18,943)”

Source: [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)

<a id="topic-2.2.1.8.2-2"></a>

###### Outpatient and injection-related resource use

> “Mean (SD) annual nAMD-related outpatient burden was 6.6 (4.8) visits overall”
> “Overall mean (SD) annual anti-VEGF–related outpatient visit burden was 3.9 (4.2) visits”

Source: [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)

<a id="topic-2.2.1.8.2-3"></a>

###### Cost by disease activity status

> “The nAMD-related outpatient visit costs were roughly 4 and roughly 7 times higher, respectively, for the active CNV group ($8,658 [SD = $11,612]) compared with the inactive CNV ($2,406 [SD = $5,510]) and inactive scar ($1,198 [SD = $3,035]) groups (P < 0.0001).”

Source: [Almony et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391196/)

<a id="topic-2.2.1.8.2-4"></a>

###### National cost estimates

> “Estimates of the global cost of visual impairment due to AMD are $343 billion, including $255 billion in direct healthcare costs.”

Source: [BrightFocus Foundation](https://www.brightfocus.org/macular/facts-figures/)

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Neovascular age-related macular degeneration on Families

<a id="topic-2.2.1.8.3-1"></a>

###### Lost work productivity and wages

> “Mean wages lost due to impaired work productivity ranged from $1,395 to $55,180.”
> “Mean wages lost due to unemployment ranged from $22,314 USD to $58,886 USD a year.”

Source: [Tran et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11067424/)

<a id="topic-2.2.1.8.3-2"></a>

###### Unemployment associated with AMD-related vision loss

> “The mean unemployment rate attributed to AMD ranged from 5.50% to 77.00%.”

Source: [Tran et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11067424/)

<a id="topic-2.2.1.8.3-3"></a>

###### Caregiver work absence and added household expense

> “22% requiring a caregiver to take time off from work for transportation.”
> “The financial burden of AMD is further exacerbated by additional expenses such as transportation costs, costs for caregivers, and healthcare costs.”

Source: [Tran et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11067424/)

<a id="topic-2.2.1.8.3-4"></a>

###### Caregiver time burden per treatment visit

> “Approximately half of the patients required caregiver support every visit (37.7%) or occasionally (14.6%)”

Source: [Reitan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10226541/)

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

Not applicable.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Anti-VEGF Monoclonal Antibodies and Antibody Fragments

<a id="topic-2.2.2.1.1-1"></a>

###### Ranibizumab mechanism of action

> “Ranibizumab binds to the receptor binding site of active forms of VEGF-A”

Source: [Genentech LUCENTIS prescribing information (2024)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d)

<a id="topic-2.2.2.1.1-2"></a>

###### Ranibizumab indication and dosing for wet AMD

> “LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD)”
> “LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).”

Source: [Genentech LUCENTIS prescribing information (2024)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 VEGF Trap Fusion Proteins

<a id="topic-2.2.2.1.2-1"></a>

###### Aflibercept mechanism of action

> “Aflibercept acts as a soluble decoy receptor that binds VEGF-A and PlGF, and thereby can inhibit the binding and activation of these cognate VEGF receptors.”

Source: [Regeneron EYLEA prescribing information (2024)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f96cfd69-da34-41ee-90a9-610a4655cd1c)

<a id="topic-2.2.2.1.2-2"></a>

###### Aflibercept indication and dosing for wet AMD

> “Neovascular (Wet) Age-Related Macular Degeneration (AMD)”
> “The recommended dose for EYLEA is 2 mg (0.05 mL of 40 mg/mL solution) administered by intravitreal injection every 4 weeks (approximately every 28 days, monthly) for the first 12 weeks (3 months), followed by 2 mg (0.05 mL of 40 mg/mL solution) via intravitreal injection once every 8 weeks (2 months).”

Source: [Regeneron EYLEA prescribing information (2024)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f96cfd69-da34-41ee-90a9-610a4655cd1c)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Bispecific Anti-VEGF/Angiopoietin-2 Antibodies

<a id="topic-2.2.2.1.3-1"></a>

###### Faricimab mechanism of action

> “Faricimab is a humanized bispecific antibody that acts through inhibition of two pathways by binding to VEGF-A and Ang-2.”

Source: [Genentech VABYSMO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04cc9ef7-c02a-4e92-a655-0062674e8487)

<a id="topic-2.2.2.1.3-2"></a>

###### Faricimab indication and extended dosing intervals

> “VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (nAMD)”

Source: [Genentech VABYSMO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04cc9ef7-c02a-4e92-a655-0062674e8487)

> “At week 48, after 4 initial monthly doses in the VABYSMO arm, 45% of patients received the Weeks 28 and 44 dosing, 33% of patients received the Weeks 24, 36 and 48 dosing, and the remaining 22% of patients received dosing every 8 weeks.”

Source: [Genentech VABYSMO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04cc9ef7-c02a-4e92-a655-0062674e8487)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Anti-VEGF Biosimilars

<a id="topic-2.2.2.1.4-1"></a>

###### Ranibizumab biosimilars

> “ranibizumab-nuna (Byooviz; Biogen/Samsung Bioepis), was approved in September 2021 for wet AMD, RVO, and myopic CNV.”
> “ranizumab-eqrn (Cimerli; Coherus Biosciences), was FDA approved in both 0.3 mg and 0.5 mg doses in October 2022 for DME, diabetic retinopathy (DR), wet AMD, RVO, and myopic CNV.”
> “first FDA-designated interchangeable biosimilar, meaning it can be substituted for reference ranibizumab at the pharmacy level”

Source: [Li and Fekrat (2023)](https://www.retinalphysician.com/issues/2023/september/the-current-landscape-of-anti-vegf-biosimilars/)

<a id="topic-2.2.2.1.4-2"></a>

###### Anticipated cost savings from biosimilars

> “biosimilars are estimated to cost patients around 30% to 40% less than the original biologic.”

Source: [Li and Fekrat (2023)](https://www.retinalphysician.com/issues/2023/september/the-current-landscape-of-anti-vegf-biosimilars/)

<a id="topic-2.2.2.1.4-3"></a>

###### Agents included in current comparative evidence

> “aflibercept 2 mg, aflibercept 8 mg, bevacizumab 1.25 mg (off‐label or on‐label), brolucizumab 6 mg, faricimab 6 mg, ranibizumab 0.5 mg, and the corresponding biosimilars.”

Source: [Lucenteforte et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805632/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Off-label Compounded Bevacizumab

<a id="topic-2.2.2.1.5-1"></a>

###### Origin of off-label use

> “ophthalmologists began treating neovascular AMD with off-label use of bevacizumab (Avastin, Genentech), since the drug had a target specificity similar to that of ranibizumab and was available at low cost.”

Source: [CATT Research Group (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3157322/)

<a id="topic-2.2.2.1.5-2"></a>

###### Comparative efficacy versus ranibizumab (CATT trial)

> “Bevacizumab administered monthly was equivalent to ranibizumab administered monthly, with 8.0 and 8.5 letters gained, respectively.”
> “At 1 year, bevacizumab and ranibizumab had equivalent effects on visual acuity when administered according to the same schedule.”

Source: [CATT Research Group (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3157322/)

<a id="topic-2.2.2.1.5-3"></a>

###### Repackaging and contamination risk

> “During March 6–8, 2013, four patients with age-related macular degeneration received a diagnosis of acute endophthalmitis”
> “Investigation of pharmacy A revealed multiple areas in which practices did not conform to United States Pharmacopeial Convention Chapter 797 standards for compounding sterile preparations or to recommended best practices for repackaging bevacizumab; these deficiencies might have contributed to bevacizumab contamination”

Source: [Edison et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4285274/)

<a id="topic-2.2.2.1.5-4"></a>

###### Clinical decision-making around bevacizumab non-response

> “For wet AMD patients who have a suboptimal response to Avastin (bevacizumab, Genentech) treatment, 88.4 percent of the physicians say they'll switch to Eylea (aflibercept, Regeneron). A smaller percentage, 11.1, say they'll switch to Lucentis.”

Source: [Review of Ophthalmology (2022)](https://www.reviewofophthalmology.com/article/retina-surgeons-share-their-treatment-preferences)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 Photodynamic Therapy and Thermal Laser Photocoagulation

<a id="topic-2.2.2.1.6-1"></a>

###### Historical role of verteporfin photodynamic therapy

> “In 2000 photodynamic therapy with verteporfin (PDT-V) was approved by the United States' Food and Drug Administration for the treatment of subfoveal CNV due to AMD.”
> “PDT-V alone has been shown in a large number of cases to require retreatments every 3 months.”

Source: [Giustolisi et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3516162/)

<a id="topic-2.2.2.1.6-2"></a>

###### National Eye Institute description of photodynamic therapy

> “Photodynamic therapy (PDT) is a much less common treatment for wet AMD that doctors sometimes use along with anti-VEGF injections.”
> “a light-sensitive medicine called verteporfin that "turns on" when hit by a specific type of laser (sometimes called a cold laser)”

Source: [National Eye Institute wet AMD treatments page](https://www.nei.nih.gov/eye-health-information/eye-conditions-and-diseases/age-related-macular-degeneration/treatments-wet-amd-advanced-neovascular-amd)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

###### Frequent injections and monitoring visits

> “requires repeated and frequent intravitreal injections of the drug, which are necessary to maintain the therapeutic effect, frequent clinical visits to monitor efficacy and safety, and a significant financial burden associated with high drug costs”

Source: [Lucenteforte et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805632/)

<a id="topic-2.2.2.1.7-2"></a>

###### Treatment burden on patients and caregivers

> “Approximately half of the patients required caregiver support every visit (37.7%) or occasionally (14.6%)”

Source: [Reitan et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10226541/)

<a id="topic-2.2.2.1.7-3"></a>

###### Contamination risk specific to repackaged bevacizumab

> “Investigation of pharmacy A revealed multiple areas in which practices did not conform to United States Pharmacopeial Convention Chapter 797 standards for compounding sterile preparations or to recommended best practices for repackaging bevacizumab; these deficiencies might have contributed to bevacizumab contamination”

Source: [Edison et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4285274/)

<a id="topic-2.2.2.1.7-4"></a>

###### Persistent fibrotic scarring despite treatment

> “long-term studies show that smaller and less severe fibrotic scars are not uncommon and develop over time despite optimal treatment.”

Source: [Armendariz et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11584703/)

<a id="topic-2.2.2.1.7-5"></a>

###### Response heterogeneity across agents and patients

> “Patients with the minor allele of rs2285714 respond worse to antiangiogenic therapy.”

Source: [Kozhevnikova et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9312436/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### First FDA-approved ophthalmic bevacizumab formulation

> “rigorous clinical evidence, validated manufacturing, approved labeling, comprehensive quality systems, and ongoing FDA regulatory oversight”
> “Rather than relying on repackaged formulations originally intended for intravenous use, physicians now have access to a purpose-built ophthalmic formulation of bevacizumab designed specifically for intravitreal administration that delivers the manufacturing consistency, product quality, and regulatory oversight patients deserve.”

Source: [Outlook Therapeutics (2026)](https://www.biospace.com/press-releases/outlook-therapeutics-announces-lytenava-fda-approval-as-the-first-and-only-fda-approved-ophthalmic-bevacizumab-for-the-treatment-of-wet-amd)

<a id="topic-2.2.2.2-2"></a>

###### Relationship to compounded/repackaged bevacizumab

> “Bevacizumab has long been used off-label as an anti-VEGF therapy for retinal diseases because of its comparatively low cost, despite lacking an FDA-approved ophthalmic formulation.”

Source: [Eyewire+ (2026)](https://eyewire.news/news/fda-approves-outlook-therapeutics-lytenava-as-first-ophthalmic-bevacizumab-for-wet-amd)

<a id="topic-2.2.2.2-3"></a>

###### Manufacturer statement on positioning

> “It's really been the retina community that has been supporting us and steadfast in sustaining us through this journey because they've been requesting and wanting an FDA-approved [formulation of bevacizumab],”
> “this is a bevacizumab that has been specifically designed for ophthalmology use, which I think is really important.”

Source: [Eyewire+ (2026)](https://eyewire.news/news/fda-approves-outlook-therapeutics-lytenava-as-first-ophthalmic-bevacizumab-for-wet-amd)

<a id="topic-2.2.2.2-4"></a>

###### Commercial launch plans and care setting

> “Outlook Therapeutics expects to make LYTENAVA™ available to eligible patients in the United States before year-end”

Source: [Outlook Therapeutics (2026)](https://www.biospace.com/press-releases/outlook-therapeutics-announces-lytenava-fda-approval-as-the-first-and-only-fda-approved-ophthalmic-bevacizumab-for-the-treatment-of-wet-amd)

<a id="topic-2.2.2.2-5"></a>

###### Market context into which Lytenava enters

> “The U.S. anti-VEGF retina market is estimated at approximately $8.5 billion annually, with millions of intravitreal injections administered every year.”

Source: [Outlook Therapeutics (2026)](https://www.biospace.com/press-releases/outlook-therapeutics-announces-lytenava-fda-approval-as-the-first-and-only-fda-approved-ophthalmic-bevacizumab-for-the-treatment-of-wet-amd)

<a id="topic-2.2.2.2-6"></a>

###### FDA-licensed indication

> “Lytenava is indicated for treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).”

Source: [FDA (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761320Orig1s000ltr.pdf)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Genetic modifiers of anti-VEGF response

> “Patients with the minor allele of rs2285714 respond worse to antiangiogenic therapy.”
> “For both rs800292 and rs6677604, carriage of the A allele was protective and decreased the nAMD risk.”

Source: [Kozhevnikova et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9312436/)

<a id="topic-2.2.2.3-2"></a>

###### Knowledge-guided individualization

> “Unraveling the association between AMD genetics and response to therapy could pave the way for personalized AMD treatment, with genetic variants serving as predictors of its outcome, treatment regimen, and dosage mode.”

Source: [Kozhevnikova et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9312436/)

<a id="topic-2.2.2.3-3"></a>

###### Lesion and dosing-driven heterogeneity across agents

> “aflibercept 2 mg, aflibercept 8 mg, bevacizumab 1.25 mg (off‐label or on‐label), brolucizumab 6 mg, faricimab 6 mg, ranibizumab 0.5 mg, and the corresponding biosimilars.”
> “One main underlying factor influencing visual outcomes is the average number of injections over time,”

Source: [Lucenteforte et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805632/)

<a id="topic-2.2.2.3-4"></a>

###### Sex-related heterogeneity in incidence and burden

> “The incidence of nAMD in women was almost two-fold greater compared to males at the same age.”

Source: [Korva-Gurung et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10262804/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Treat-and-extend regimens

> “requires repeated and frequent intravitreal injections of the drug, which are necessary to maintain the therapeutic effect, frequent clinical visits to monitor efficacy and safety, and a significant financial burden associated with high drug costs”
> “monthly, monthly for the first three months followed by PRN, every eight weeks, quarterly cross‐over from monthly to PRN, and treat‐and‐extend protocols”

Source: [Lucenteforte et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12805632/)

<a id="topic-2.2.2.4-2"></a>

###### Home optical coherence tomography as a safety net between visits

> “Home-based optical coherence tomography (OCT) has emerged as a potential tool to bridge this surveillance gap by enabling frequent, patient-administered imaging between office visits”
> “Persistent or recurring fluid was identified in 121 (65%) intervals, on average 32 days prior to the next office visit.”
> “Home OCT monitoring provides adjunctive information to support early detection of fluid and may facilitate timely clinical evaluation.”

Source: [Sambhara et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13413994/)

<a id="topic-2.2.2.4-3"></a>

###### Amsler grid self-monitoring between visits

> “Its portability and ease of use enable patients to participate actively in the management of their ocular health, allowing earlier detection of disease progression and more timely medical intervention.”

Source: [Estreicher et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12912174/)

<a id="topic-2.2.2.4-4"></a>

###### Extended-interval dosing to reduce visit burden

> “At week 48, after 4 initial monthly doses in the VABYSMO arm, 45% of patients received the Weeks 28 and 44 dosing, 33% of patients received the Weeks 24, 36 and 48 dosing, and the remaining 22% of patients received dosing every 8 weeks.”

Source: [Genentech VABYSMO prescribing information (2026)](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04cc9ef7-c02a-4e92-a655-0062674e8487)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

<a id="topic-2.2.2.5-1"></a>

###### Postmarketing commitment on reference standard qualification

> “We remind you of your postmarketing commitment: 5036-1 Implement a two-tiered reference standard system by qualifying a working reference standard. Submit the qualification report(s) and requalification protocol for the working reference standard in a Prior Approval Supplement to the BLA.”
> “The timetable you submitted on July 17, 2026, states that you will conduct this study according to the following schedule: Final Report Submission: 7/2027”

Source: [FDA (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761320Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-2"></a>

###### Pediatric study waiver

> “We are waiving the pediatric study requirement for this application because necessary studies are impossible or highly impracticable as the conditions rarely or never occur in pediatrics.”

Source: [FDA (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761320Orig1s000ltr.pdf)

<a id="topic-2.2.2.5-3"></a>

###### No advisory committee referral

> “Your application for Lytenava was not referred to an FDA advisory committee because this biologic is not the first in its class.”

Source: [FDA (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761320Orig1s000ltr.pdf)

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

<a id="topic-2.2.2.6-1"></a>

###### Adverse experience and distribution reporting

> “You must submit adverse experience reports under the adverse experience reporting requirements at 21 CFR 600.80.”
> “You must submit distribution reports under the distribution reporting requirements at 21 CFR 600.81.”

Source: [FDA (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761320Orig1s000ltr.pdf)

<a id="topic-2.2.2.6-2"></a>

###### Biological product deviation reporting

> “You must submit reports of biological product deviations under 21 CFR 600.14. You should promptly identify and investigate all manufacturing deviations, including those associated with processing, testing, packing, labeling, storage, holding and distribution.”

Source: [FDA (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761320Orig1s000ltr.pdf)

<a id="topic-2.2.2.6-3"></a>

###### Manufacturing change control

> “Any changes in the manufacturing, testing, packaging, or labeling of Lytenava, or in the manufacturing facilities, will require the submission of information to your BLA for our review and written approval, consistent with 21 CFR 601.12.”

Source: [FDA (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761320Orig1s000ltr.pdf)

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Vision stabilization and improvement with anti-VEGF therapy

> “Anti-VEGF treatment improves vision in about one third (1 out of 3) people who take it.”
> “For a vast majority (9 out of 10), it at least stabilizes vision.”

Source: [American Academy of Ophthalmology](https://www.aao.org/eye-health/drugs/anti-vegf-treatments)

<a id="topic-2.2.2.7-2"></a>

###### Contrast with untreated natural history

> “ranibizumab not only prevented loss of vision in nAMD treatment-naïve patients (the natural history for these patients), but also, and for the first time ever in this disease, that their vision could recover, as shown by the 7.2 letters gained on average in the ranibizumab 0.5 mg dose group (the dose subsequently marketed) versus an average loss of 10.4 letters by the sham group.”

Source: [Armendariz et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11584703/)

<a id="topic-2.2.2.7-3"></a>

###### Persistence of fibrotic scarring as a limit on outcomes

> “long-term studies show that smaller and less severe fibrotic scars are not uncommon and develop over time despite optimal treatment.”

Source: [Armendariz et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11584703/)

## Related pages
- [Lytenava (bevacizumab-vikg): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Terms and abbreviations](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/terms-and-abbreviations.md)
- [Lytenava (bevacizumab-vikg): Neovascular age-related macular degeneration](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/executive-summary.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/clinical-evidence.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/economics.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: References](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/references.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: drug evaluation](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/oregon) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/oregon.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: new drug review](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/review) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/review.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: prevalence by geography](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/prevalence) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/prevalence.md)
- [Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/cost-effectiveness-analyses.md)
